Array BioPharma (NASDAQ:ARRY): Outperform Rating was Reaffirmed by Researchers at Wells Fargo; with PT of $33.

June 29, 2018 - By Samuel McNeil

Array BioPharma Inc. (NASDAQ:ARRY) Corporate Logo

Big Money Sentiment increased to 1.74 in 2018 Q1. It has change of 0.44, from 2017Q4’s 1.3. The ratio improved due to Array BioPharma Inc. positioning: 16 sold and 54 reduced. 55 funds bought stakes and 67 increased stakes. Investors holded 194.11 million in 2017Q4 but now own 189.71 million shares or 2.27% less.

17,697 were accumulated by Trexquant Invest Lp. Pointstate Capital Limited Partnership holds 973,700 shs or 0.17% of its capital. Natl Bank Of Montreal Can owns 2,508 shs. The New Jersey-based Nj State Employees Deferred Compensation Plan has invested 0.06% in Array BioPharma Inc. (NASDAQ:ARRY). Bnp Paribas Arbitrage Sa has invested 0% of its capital in Array BioPharma Inc. (NASDAQ:ARRY). Gsa Capital Prns Ltd Liability Partnership reported 0.01% of its capital in Array BioPharma Inc. (NASDAQ:ARRY). Wells Fargo & Com Mn reported 2.40 million shs. Bancorporation Of Nova Scotia accumulated 122,600 shs. Los Angeles Capital And Equity Incorporated holds 0.01% or 116,725 shs in its capital. Advisory Incorporated stated it has 54,534 shs. Nebraska-based Ameritas Investment Prtn has invested 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). Amer Intl has invested 0.01% in Array BioPharma Inc. (NASDAQ:ARRY). Balyasny Asset Limited Liability Com has 0.02% invested in Array BioPharma Inc. (NASDAQ:ARRY) for 317,608 shs. Driehaus Cap Mngmt Limited Liability has 1.55% invested in Array BioPharma Inc. (NASDAQ:ARRY). Fiera Corp holds 0.01% in Array BioPharma Inc. (NASDAQ:ARRY) or 167,035 shs.

Array BioPharma Inc. registered $6.95 million net activity with 0 buys and 11 insider sales since January 16, 2018. On Wednesday, June 20 Shares for $410,220 were sold by VAN LUNSEN GIL J. Haddock Jason sold $102,975 worth of Array BioPharma Inc. (NASDAQ:ARRY) on Tuesday, January 16.

Reiterated Array BioPharma (NASDAQ:ARRY) Rating.

New York: On Thursday, 28 June, a research report was shared with investors of Array BioPharma (NASDAQ:ARRY). Its Outperform Rating reconfirmed at Wells Fargo. Equity analysts have price target of $33 which suggests 98.08 % upside potential on firm’s stock.

Array BioPharma Inc. (NASDAQ:ARRY) Ratings Coverage

Total analysts of 7 have positions in Array Biopharma (NASDAQ:ARRY) as follows: 7 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since January 21, 2018 according to StockzIntelligence Inc Array Biopharma has 13 analyst reports. The stock rating was maintained by Stifel Nicolaus with “Buy” on Sunday, January 21. On Monday, January 22 the stock has “Outperform” rating by Leerink Swann. On Monday, June 25 the rating was maintained by Cantor Fitzgerald with “Overweight”. In Thursday, May 10 report Cowen & Co maintained the stock with “Buy” rating. On Tuesday, February 6 the stock has “Buy” rating by Stifel Nicolaus. On Sunday, January 21 the stock has “Buy” rating by Cowen & Co. On Tuesday, February 6 SunTrust maintained Array BioPharma Inc. (NASDAQ:ARRY) rating. SunTrust has “Buy” rating and $20.0 target. The company rating was maintained by Wells Fargo on Thursday, June 28. On Tuesday, June 5 the rating was maintained by Cowen & Co with “Buy”. On Monday, June 25 Piper Jaffray maintained the shares of ARRY in report with “Buy” rating.

ARRY touched $16.66 during the last trading session after $0.24 change.Currently Array BioPharma Inc. is uptrending after 92.14% change in last June 29, 2017. ARRY has also 1.40M shares volume. ARRY outperformed the S&P500 by 79.57%.

On August, 8 Array BioPharma Inc. (NASDAQ:ARRY)’s earnings report is anticipated by WallStreet, RTT reports. Analysts predict 47.06 % diference or $-0.25 from the $-0.17 EPS from 2017. Wall Street forecasts 127.27 % negative EPS growth as of August, 8.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.The firm is valued at $3.51 billion. The company's drugs in Phase III clinical trials include Binimetinib, Encorafenib, Selumetinib, and Ipatasertib/GDC-0068 for the treatment of cancer, as well as ASC08/Danoprevir to treat hepatitis C virus.Last it reported negative earnings. The Company’s drug candidates in Phase II/registration trials comprise Larotrectinib/LOXO-101, a PanTrk inhibitor for cancer; Tucatinib/ONT-380, a HER2 inhibitor for breast cancer; and Varlitinib/ASLAN001, a Pan-HER2 inhibitor for gastric or breast cancer.

For more Array BioPharma Inc. (NASDAQ:ARRY) news posted briefly go to: Fool.com, Seekingalpha.com, Benzinga.com, Benzinga.com or Nasdaq.com. The titles are as follows: “George Soros Bought This Clinical-Stage Biotech Stock. Should You?” posted on May 31, 2018, “Key events next week – healthcare” on June 21, 2018, “Piper Jaffray, Stifel Defend Array Biopharma As Stock Falls On Profit-Taking” with a publish date: June 28, 2018, “Jordyn Fantuzzi” and the last “3 Biotechs With Huge FDA Decisions in June” with publication date: May 31, 2018.

Array BioPharma Inc. (NASDAQ:ARRY) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: